GUSELKUMAB (Tremfya) prior authorization at CareFirst BCBS
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
CareFirst BCBS requires Interleukin-23 Antagonist prior-authorization documentation for GUSELKUMAB (Tremfya): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
CareFirst BCBS reviews GUSELKUMAB (Tremfya) prior authorizations against its medical policy for Interleukin-23 Antagonist. CareFirst BCBS-specific context: BCBS licensee for Maryland, DC, and northern Virginia (~3.5M members). Operates as non-profit. Appeals jurisdiction depends on policy issue location — MIA (MD), DISB (DC), or SCC Bureau of Insurance (VA). CVS Caremark is the PBM.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in Interleukin-23 Antagonist
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- CareFirst BCBS's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- DC/MD/VA cross-jurisdiction issues
- Step therapy on specialty drugs via CVS Caremark
- Behavioral health network adequacy
- BlueChoice HMO referral denials
GUSELKUMAB (Tremfya)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- Step therapy requiring adalimumab biosimilar before IL-23
- Step therapy requiring ustekinumab first
- Prior auth missing PASI 75 failure documentation on prior biologic
- Indication restriction (psoriasis only, denying PsA or UC use)
Brand: Tremfya. Selective IL-23 (p19) inhibitor. FDA-approved for plaque psoriasis, PsA, and added ulcerative colitis indication September 2024. First IL-23 with UC approval.
Manufacturer patient-assistance program: Janssen CarePath — relevant when a CareFirst BCBS denial sticks and the patient needs bridge access while appealing.
How CareFirst BCBS approaches Biologic drugs (mAbs and biosimilars) PAs
For GUSELKUMAB (TREMFYA), check whether the current CareFirst BCBS Biologic drugs (mAbs and biosimilars) policy cites step therapy on specialty drugs via cvs caremark. Pharmacy-benefit review for GUSELKUMAB (TREMFYA) at CareFirst BCBS is routed through CVS Caremark. The applicable review clock depends on the member's current product, whether the request is complete and urgent, and governing plan rules. Confirm receipt and timing with CareFirst BCBS; if denied, use the filing date and route printed on that denial notice. CareFirst BCBS's utilization-management vendor (Carelon, eviCore, OptumRx, or in-house) sets the step-therapy ladder — appeals that cite ACR, AAD, or AGA guideline language directly to the medical director shorten escalation. CareFirst BCBS is domiciled in MD, so unresolved appeals escalate to the MD insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead).
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://provider.carefirst.com) with the same packet plus an applicable, current clinical source supporting GUSELKUMAB (Tremfya)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a CareFirst BCBS denial on DenialHelp.
Contact CareFirst BCBS
- Provider portal: https://provider.carefirst.com
Frequently asked questions
What documentation does CareFirst BCBS need for GUSELKUMAB (Tremfya) prior auth?
CareFirst BCBS's typical PA packet for GUSELKUMAB (Tremfya): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For Interleukin-23 Antagonist, expect clinical-criteria documentation specific to this class.
What's the turnaround time at CareFirst BCBS?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for GUSELKUMAB (Tremfya) at CareFirst BCBS?
Preparation scenarios to check against the current notice and policy include: DC/MD/VA cross-jurisdiction issues; Step therapy on specialty drugs via CVS Caremark; Behavioral health network adequacy. These are not measured frequency claims. For GUSELKUMAB (Tremfya), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
What prior failures does CareFirst BCBS typically require before approving GUSELKUMAB (TREMFYA)?
CareFirst BCBS's biologics step-therapy ladder for most indications begins with a conventional DMARD (methotrexate, sulfasalazine, leflunomide) or topical/inhaled first-line, then a step-1 biologic (typically a TNF inhibitor or adalimumab biosimilar), then the requested agent. Document trial duration (≥12 weeks for most biologics), dosing reached, and reason for discontinuation (inadequate response by disease-activity score, intolerance, or contraindication). For GUSELKUMAB (TREMFYA), attach the specific disease-activity instrument CareFirst BCBS accepts (e.g., DAS28, PASI 75, HBI, Mayo) — appeals with raw symptom narrative but no scored instrument carry higher denial rates. Pharmacy-benefit handling is routed through CVS Caremark. External-review escalation for CareFirst BCBS fully-insured policies sits with the MD insurance department.
How do I prep for a peer-to-peer with CareFirst BCBS on GUSELKUMAB (Tremfya)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the GUSELKUMAB (Tremfya) PA packet
Open ApprovalHelp — generate a GUSELKUMAB (Tremfya) prior-auth packet tailored to CareFirst BCBS's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com